PCA
VKTX icon

Pallas Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Pallas Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,661
Closed -$797K – 975
2025
Q4 		$797K Hold
22,661
– – 0.03% 412
2025
Q3 		$596K Buy
22,661
+386
+2% +$11.5K 0.02% 475
2025
Q2 		$590K Buy
22,275
+1,127
+5% +$29.7K 0.02% 450
2025
Q1 		$511K Sell
21,148
-92
-0.4% -$2.91K 0.02% 457
2024
Q4 		$855K Sell
21,240
-165
-0.8% -$9.41K 0.04% 264
2024
Q3 		$1.57M Buy
21,405
+2,062
+11% +$121K 0.07% 167
2024
Q2 		$969K Buy
19,343
+4,426
+30% +$290K 0.04% 216
2024
Q1 		$1.22M Buy
14,917
+551
+4% +$24.5K 0.05% 193
2023
Q4 		$267K Buy
14,366
+917
+7% +$12K 0.01% 327
2023
Q3 		$129K Hold
13,449
– – 0.01% 337
2023
Q2 		$208K Buy
+13,449
New +$282K 0.01% 251

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pallas Capital Advisors's VKTX Position: Q1 2026 in Review

Pallas Capital Advisors sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 22,661 shares — an estimated $797K sold.

Pallas Capital Advisors first reported a position in VKTX in Q2 2023 and held it in 11 quarters. The position peaked at $1.57M in Q3 2024. 414 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Pallas Capital Advisors reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 22,661 Viking Therapeutics shares in Q1 2026, an estimated $797K.
  • Pallas Capital Advisors first reported a position in Viking Therapeutics in Q2 2023 and held it in 11 quarters.
  • Pallas Capital Advisors's Viking Therapeutics position peaked at $1.57M in Q3 2024.
  • 414 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.